Navigation Links
STERIS Corporation Announces Fiscal 2010 First Quarter Results
Date:7/30/2009

MENTOR, Ohio, July 30 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced financial results for its fiscal 2010 first quarter ended June 30, 2009. Fiscal 2010 first quarter revenues were $283.5 million compared with $311.6 million in the first quarter of fiscal 2009, a decline of 9%. On a constant currency basis, revenues decreased 7%. Operating profit increased 22% to $42.9 million, or 15.1% of revenues, compared with $35.0 million, or 11.2% of revenues in the first quarter of fiscal 2009. Fiscal 2010 first quarter net income was $25.5 million, or $0.43 per diluted share, compared with net income of $25.5 million, or $0.43 per diluted share, in the first quarter of fiscal 2009.

"While our first quarter proved to be challenging from a top-line perspective, we are pleased with our solid operating performance," said Walt Rosebrough, President and Chief Executive Officer of STERIS. "In particular, capital equipment in our Healthcare segment was impacted by challenging market dynamics as well as the timing of shipments. However, we are cautiously optimistic that our year-over-year growth rates will improve in the coming quarters, and are increasingly comfortable with our earnings per share guidance. As a result, our outlook for the full fiscal year is unchanged."

Segment Results

Healthcare revenues in the quarter were $200.6 million compared with $224.1 million in the first quarter of fiscal 2009, a decline of 10%. Strength in consumables was more than offset by declines in capital equipment and service, reflecting lower spending by hospital Customers across most major product categories. Backlog levels at quarter end were $132.4 million, an increase of 16% compared with the same time last year. Operating income was $32.1 million, an increase of 10% compared with the prior year period, driven by efficiency initiatives across the segment.

Life Sciences first quarter revenues were $46.1 million compared with $48.0 million in the first quarter of fiscal 2009, a decline of 4%. Strength in consumables was more than offset by a decline in capital equipment and service revenues. Backlog levels at quarter end were $46.3 million, a decline of 7% compared with the prior year period. Life Sciences operating income was $4.8 million, an increase of $3.7 million compared with the prior year period, driven by our focus on higher margin capital equipment and overall operating efficiencies.

Fiscal 2010 first quarter revenues for Isomedix Services were $35.4 million compared with $36.9 million in the same period last year, a decline of 4%. Revenues were affected by the previously disclosed sale of two facilities during fiscal 2009, which were partially offset by a modest improvement in demand from medical device Customers. Operating income was $8.3 million in the quarter compared with $8.2 million in the first quarter of last year.

Cash Flow

Net cash provided by operations for the first quarter of fiscal 2010 was $32.6 million, compared with net cash provided by operations of $28.7 million in the same period last year. Free cash flow (see note 1) for the first quarter of fiscal 2010 was $24.4 million, compared with free cash flow of $18.1 million in the prior year quarter. The growth in free cash flow was driven by improved working capital management and lower capital spending.

Regular Quarterly Dividend Announced

The Company also announced today that STERIS's Board of Directors has authorized a regular quarterly dividend in the amount of $0.11 per common share. The dividend is payable September 17, 2009 to shareholders of record at the close of business on August 20, 2009.

Outlook

Based upon first quarter results and current anticipated trends, the Company's expectations are unchanged for the full fiscal year, with revenues flat to down mid-single digits and earnings per diluted share of $1.80 to $2.00. This outlook assumes the average forward exchange rates for the U.S. dollar and key international currencies as of June 30, 2009. Refer to the earnings announcement dated May 7, 2009 for the detailed full year outlook and other assumptions.

Conference Call

In conjunction with this release, STERIS Corporation management will host a conference call today at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-800-369-8428 in the United States and Canada, and 1-773-799-3378 internationally, then referencing the password "STERIS".

For those unable to listen to the conference call live, a replay will be available from 12:00 p.m. Eastern time on July 30, 2009, until 5:00 p.m. Eastern time on August 13, 2009, either over the Internet at www.steris-ir.com or via phone by calling 1-866-416-1187 in the United States and Canada, and 1-203-369-0718 internationally.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.

(1) Free cash flow is a non-GAAP number used by the Company as a measure to gauge its ability to fund future growth opportunities, repurchase common shares, and pay cash dividends. Free cash flow is defined as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net, plus proceeds from the sale of property, plant, equipment and intangibles. STERIS's calculation of free cash flow may vary from other companies.

This news release, and the conference call referenced here, may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "potential," "confidence," "improve," "optimistic," "comfortable," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any outcome from litigation, regulatory action, administrative proceedings, government investigations, warning letters, cost reductions, business strategies, level of share repurchases or dividends, earnings and revenue trends, expense reduction or other future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation previously disclosed FDA warning letters and government investigations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated cost savings or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release, and the conference call referenced here, may adversely impact Company performance, results, or value, (g) the effect of the credit crisis on our ability, as well as the ability of our customers and suppliers, to adequately access the credit markets when needed, and (h) those risks described in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 30, 2009, under Item 1A, "Risk Factors."

    STERIS Corporation
    Consolidated Condensed Statements of Income
    (In thousands, except per share data)

                                                      Three Months Ended
                                                           June 30,
                                                          ----------
                                                     2009           2008
                                                     ----           ----
                                                 (Unaudited)    (Unaudited)

      Revenues                                     $283,543       $311,565
      Cost of revenues                              158,707        181,064
                                                    -------        -------
      Gross profit                                  124,836        130,501

      Operating expenses:
        Selling, general, and administrative         74,605         87,348
        Research and development                      7,580          8,279
        Restructuring expense                          (211)          (166)
                                                       ----           ----
      Total operating expenses                       81,974         95,461
                                                     ------         ------

      Income from operations                         42,862         35,040
      Non-operating expense, net                      2,865          1,385
      Income tax expense                             14,455          8,155
                                                     ------          -----
      Net income                                    $25,542        $25,500
                                                    =======        =======

      Earnings per common share (EPS) data:
           Basic                                      $0.44          $0.43
                                                      =====          =====
           Diluted                                    $0.43          $0.43
                                                      =====          =====

      Cash dividends declared per common
       share outstanding                              $0.11          $0.06

      Weighted average number of common
       shares outstanding used in EPS
       computation:
        Basic number of common shares
         outstanding                                 58,517         58,694
        Diluted number of common shares
         outstanding                                 58,984         59,647



    STERIS Corporation
    Consolidated Condensed Balance Sheets
    (In thousands)
                                                   June 30,        March 31,
                                                     2009            2009
                                                     ----            ----
    Assets                                        (Unaudited)
    Current assets:
      Cash and cash equivalents                    $176,072       $154,180
      Accounts receivable, net                      205,327        238,438
      Inventories, net                              137,533        130,218
      Other current assets                           25,053         30,294
                                                     ------         ------
        Total Current Assets                        543,985        553,130

      Property, plant, and
       equipment, net                               350,171        350,996
      Goodwill and intangible
       assets, net                                  312,991        305,189
      Other assets                                    8,050          7,624
                                                      -----          -----
    Total Assets                                 $1,215,197     $1,216,939
                                                 ==========     ==========

    Liabilities and Equity
    Current liabilities:
      Accounts payable                              $51,514        $68,573
      Other current liabilities                     113,309        133,453
                                                    -------        -------
        Total Current Liabilities                   164,823        202,026

      Long-term debt                                210,000        210,000
      Other liabilities                              76,632         86,748
      Equity                                        763,742        718,165
                                                    -------        -------
    Total Liabilities and Equity                 $1,215,197     $1,216,939
                                                 ==========     ==========



    STERIS Corporation
    Consolidated Condensed Statements
     of Cash Flows
    (In thousands)
                                                      Three Months Ended
                                                           June 30,
                                                          ----------
                                                      2009           2008
                                                      ----           ----
                                                   (Unaudited)    (Unaudited)
      Operating Activities:
        Net income                                  $25,542        $25,500
        Non-cash items                               11,568         20,971
        Working capital adjustments                  (4,490)       (17,744)
                                                     ------        -------
      Net cash provided by operating activities      32,620         28,727

      Investing Activities:
        Purchases of property, plant, equipment,
         and intangibles, net                        (8,355)       (10,615)
        Proceeds from sale of property, plant,
         equipment and intangibles                      175              7
                                                        ---              -
      Net cash used in investing activities          (8,180)       (10,608)

      Financing Activities:
        (Payments) proceeds under credit
         facilities, net                                  -         (1,720)
        Repurchases of common shares                      -        (31,584)
        Cash dividends paid to common shareholders   (6,441)        (3,513)
        Tax benefit from stock options exercised         47          1,413
        Stock options and other equity
         transactions, net                              152         14,302
                                                        ---         ------
      Net cash used in financing activities          (6,242)       (21,102)
      Effect of exchange rate changes on cash
       and cash equivalents                           3,694            153
                                                      -----            ---
      Increase in cash and cash equivalents          21,892         (2,830)
      Cash and cash equivalents at
       beginning of period                          154,180         51,868
                                                    -------         ------
      Cash and cash equivalents at end of period   $176,072        $49,038
                                                   ========        =======



    STERIS Corporation
    Segment Data
    (In thousands)
                                                      Three Months Ended
                                                           June 30,
                                                          ----------
                                                      2009           2008
                                                      ----           ----
                                                  (Unaudited)    (Unaudited)
      Segment Revenues:

        Healthcare                                 $200,604       $224,065
        Life Sciences                                46,116         48,039
        STERIS Isomedix Services                     35,407         36,863
                                                     ------         ------
        Total Reportable Segments                   282,127        308,967
        Corporate and Other                           1,416          2,598
                                                      -----          -----
      Total Segment Revenues                       $283,543       $311,565
                                                   ========       ========


      Segment Operating Income (Loss):

        Healthcare                                  $32,102        $29,230
        Life Sciences                                 4,779          1,047
        STERIS Isomedix Services                      8,339          8,187
                                                      -----          -----
        Total Reportable Segments                    45,220         38,464
        Corporate and Other                          (2,358)        (3,424)
                                                     ------         ------
      Total Segment Operating Income                $42,862        $35,040
                                                    =======        =======



    STERIS Corporation
    Non-GAAP Disclosures (Unaudited)
    (In thousands, except per share data)

    The following table presents financial measures which are considered to
    be "non-GAAP financial measures" under Securities Exchange Commissions
    rules. Free cash flow is defined by the Company as cash flows from
    operating activities less purchases of property, plant, equipment and
    intangibles, net (capital expenditures), plus proceeds from the sale of
    property, plant, equipment and intangibles. The Company uses free cash
    flow as a measure to gauge its ability to fund future growth
    opportunities, repurchase common shares, and pay cash dividends. STERIS's
    calculation of free cash flow may vary from other companies.


                                                    Three Months Ended
                                                          June 30,
                                                         ----------
                                                     2009           2008
                                                     ----           ----
                                                  (Unaudited)    (Unaudited)
    Calculation of Free Cash Flow:

      Cash flows from operating activities          $32,620        $28,727
      Purchases of property, plant, equipment,
       and intangibles, net                          (8,355)       (10,615)
      Proceeds from the sale of property, plant,
       equipment, and intangibles                       175              7
                                                        ---              -
    Free Cash Flow                                  $24,440        $18,119
                                                    =======        =======


'/>"/>
SOURCE STERIS Corporation
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. STERIS Corporation Announces Date of Fiscal 2010 First Quarter Earnings Release and Conference Call
2. Medical Device Sterilization Seminar Offered by STERIS Isomedix Services
3. STERIS Corporation Announces Quarterly Dividend Increase of 38%
4. STERIS Corporation Announces Date of Fiscal 2009 Fourth Quarter and Full Year Earnings Release and Conference Call
5. STERIS Corporation Announces Fiscal 2009 Third Quarter Results
6. STERIS Corporation Declares Regular Quarterly Dividend
7. STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter
8. STERIS Isomedix Services Offers Medical Device Sterilization Seminar
9. STERIS Corporation Postpones Analyst Day
10. STERIS Corporation Announces Webcast of Analyst Conference
11. STERIS Isomedix Services Offers Gamma Engineering Run Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
Breaking Medicine Technology: